| Structure–activity relationship study of dexrazoxane analogues reveals ICRF-193 as the most potent bisdioxopiperazine against anthracycline toxicity to cardiomyocytes due to … A Jirkovská, G Karabanovich, J Kubes, V Skalická, I Melnikova, ... Journal of medicinal chemistry 64 (7), 3997-4019, 2021 | 23 | 2021 |
| Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity H Bavlovič Piskáčková, H Jansová, J Kubeš, G Karabanovich, N Váňová, ... Scientific Reports 11 (1), 4456, 2021 | 11 | 2021 |
| Non-catalyzed addition of heterocyclic thiols and 5-substituted-1H-tetrazoles to vinyl ethers I Melnikova, J Roh, J Kuneš, T Artamonova, Y Zevatskii, L Myznikov Tetrahedron letters 58 (40), 3842-3845, 2017 | 9 | 2017 |
| The UHPLC-UV method applied for the forced degradation study of ixazomib and HRMS identification of its degradation products P Hatokova, V Sestak, HB Piskackova, I Melnikova, J Roh, ... Journal of Pharmaceutical and Biomedical Analysis 225, 115220, 2023 | 2 | 2023 |
| Exploring the effects of topoisomerase II inhibitor XK469 on anthracycline cardiotoxicity and DNA damage V Keresteš, J Kubeš, L Applová, P Kollárová, O Lenčová-Popelová, ... Toxicological Sciences, kfae008, 2024 | | 2024 |
